AMS: Initiation – Expanding Product Suite & Markets, Launching O&O Initiative
By M. Marin
NYSE:AMS
READ THE FULL AMS RESEARCH REPORT
Building on strong traditional core business that generates strong, steady cash flow …
Founded in 1983, American Shared Hospital Services (NYSE:AMS) has an established business and revenue streams developed over its 40-year operating history. AMS provides stereotactic radiosurgery equipment and advanced radiation therapy treatment systems to treat cancer patients. The company’s core business generates steady positive annual cash flow and forms a strong base on which AMS is adding new business lines and revenue streams to fuel incremental grow. Specifically, under a realigned management team, the company has embarked on an expansion strategy aimed at diversifying and expanding its product portfolio, entering new geographies, boosting revenue, and developing new business lines within its focus area along the cancer care continuum illustrated below, including taking stakes in certain treatment centers to capture more of the expected profits and upside.
Traditional business model can support new product lines and growing operations
AMS has embarked on a growth strategy aimed at boosting and diversifying revenue, expanding its product portfolio, entering new geographies, and developing new related business lines. The company's most important product has been the Leksell Gamma Knife®, a non-invasive advanced type of radiosurgery that has multiple advantages over traditional surgery, but which requires a substantial upfront capital investment. AMS provides financial and other solutions that enable medical centers to offer these and other costly radiation therapy services. The company conducts its Gamma Knife operations through a JV (AMS holds 81%), with the manufacturer holding 19%. The company has developed a partnership model with medical center partners that it expects will facilitate its expansion into other related businesses and products.
Expanding into new business lines such as PBRT, Linear Accelerator, others and International operations …
For example, with the installation of its first Proton Beam Radiation Therapy (PBRT) device in 2016, AMS began to diversify its revenue. PBRT revenue represented about 45% of the total in 2022 and the company targets further diversification, including expanding PBRT and other newer business lines. Moreover, with international expansion in mind, AMS has Gamma Knife and other operations in Peru and Ecuador and a new site in Mexico with a Versa HD Linear Accelerator. AMS expects to continue expanding its footprint over time both internationally and domestically.
AMS works with large OEMs that offer clinical treatment systems and software that treat cancer using radiation therapy and radiosurgery. The major products for which the company provides financial and other services include:
▪ Leksell Gamma Knife®, through a partnership with Elekta AB
▪ Advanced Linear Accelerators (LINACS)
▪ Proton Beam Radiation Therapy systems (PBRT)
▪ MR Guided Radiation Therapy Linacs (MR LINACS)
▪ Brachytherapy Suites and systems
Taking stakes in certain treatment centers to capture more of the expected profits and upside.…
To further enhance growth, AMS has launched a model to own and operate (O&O) equipment at select locations and capture more of the expected profits. The company has Peru and Ecuador centers that are standalone O&O Gamma Knife cancer treatment facilities. In addition to international Gamma Knife locations, the company also has a new site in Puebla, Mexico with a Versa HD Linear Accelerator that is slated to begin treating patients in early 2024. The Puebla, Mexico facility is the company’s newest cancer center and a joint venture. Per the O&O and diversification initiatives, AMS is acquiring 60% interest in three Rhode Island radiation therapy cancer centers equipped with Linear Accelerators (LINACs). The LINACs will further diversify revenue and expand the O&O footprint. The transaction is expected to be completed in 1H 2024.
Strong balance sheet, cash flow to support growth initiatives …
The company has a strong balance sheet and generates steady cash flow to support its growth strategy. AMS had $14.5 million i cash as of 3Q23 and annual cash flow from operations has averaged $8 million since 2013. To enhance its financial flexibility, AMS entered into a new credit agreement in 2021 that includes a $7 million revolving line of credit, which was untapped as of October 2023.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.
